The greatest danger of building outside the SF bubble is not a lack of capital, but the absence of a peer group that normalizes struggle. Without that support, founders are more susceptible to the surrounding skeptical culture and more likely to give up during inevitable downturns.

A European founder targeting the US market shouldn't dismiss European VCs. You might be the top priority in a European firm's portfolio, receiving more attention and support than you would as a lower-priority deal for a top-tier, oversubscribed Silicon Valley firm.

While lacking investor density, cities like Houston thrive by tapping into world-class academic medical centers (e.g., MD Anderson) for talent and collaborations. Furthermore, significant state-level funding, like Texas's CPRIT, can bridge the early-stage capital gap often filled by local VCs in major hubs.

The potential exodus of VCs to tax-friendly states like Florida doesn't mean Silicon Valley is dead. Instead, it could lead to a decoupling where startups remain in talent hubs like the Bay Area, while founders travel to distinct fundraising hubs—like a 'Sand Hill Road in Miami'—for capital roadshows.

A VC advises Korean entrepreneurs to abandon gradual US entry strategies. The effective model is to "parachute" in—relocating solo to a hub like Boston and immersing oneself in the network. This radical, face-time-centric approach is deemed essential for building the momentum needed for US investment and partnerships.

Raising venture capital is often a network-driven game. If you don't already have a network of VCs or a clear path through an accelerator, your focus should not be on fundraising. Instead, dedicate your effort to building a product people want and gaining traction. VCs will find you once you have something compelling to show.

Founded in Minnesota, Cellcuity taps the University of Minnesota and the region's medical device industry for scientific talent. For specialized roles like clinical development, it embraces a distributed team, demonstrating a viable model for building a biopharma company outside of traditional hubs.

According to Y Combinator partners, the network effects and density of talent, capital, and customers in San Francisco are so powerful that being physically based there can double a startup's chances of reaching a billion-dollar valuation compared to other major tech hubs like New York.

Instead of choosing between tech hubs like Austin and San Francisco, founders can adopt a hybrid model. Spend a concentrated period (1-3 months) in a high-density talent hub like SF to build domain expertise and relationships, then apply that capital back in a lower-cost home base.